Molecular Medicine Reports Molecular Medicine Reports 1791-2997 1791-3004 D.A. Spandidos 10.3892/mmr.2019.10455 mmr-20-03-2177 Articles Associations between the single nucleotide polymorphisms of APOBEC3A, APOBEC3B and APOBEC3H, and chronic hepatitis B progression and hepatocellular carcinoma in a Chinese population HeXiuting 1 XuHongqin 2 WangXiaomei 2 WuJing 1 NiuJunqi 2 GaoPujun 2 Department of Geriatrics, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China Department of Hepatology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China Correspondence to: Dr Pujun Gao or Dr Junqi Niu, Department of Hepatology, The First Hospital of Jilin University, 71 Xinmin Street, Changyang, Changchun, Jilin 130021, P.R. China, E-mail: gaopujun_18@yeah.net, E-mail: junqiniu@yahoo.com.cn 092019 02072019 20 3 2177 2188 30112018 04062019 Copyright: © He et al. 2019 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The present study examined the relationships between the single nucleotide polymorphisms (SNPs) of three members of the apolipoprotein B mRNA-editing catalytic polypeptide-like 3 (A3) gene family, A3A, A3B and A3H, and hepatitis B virus (HBV) infection and hepatocellular carcinoma (HCC) in a Han Chinese population. A total of 654 patients were enrolled in the study between January 2012 and July 2016, including 104 patients with chronic HBV infection (CHB), 265 patients with HBV-related liver cirrhosis and 285 patients with HBV-related HCC. A total of two A3A SNPs (rs7286317 and rs7290153), three A3B SNPs (rs2267398, rs2267401 and rs2076109), and five A3H SNPs (rs56695217, rs139302, rs139297, rs139316 and rs139292) were genotyped using a MassArray system. Statistical analysis and haplotype estimation were conducted using Haploview and Unphased software. No significant associations were observed between the A3A, A3B and A3H SNPs and the development of CHB and HCC. Haplotype analysis revealed that the mutant haplotypes C-T-A, C-T-G, T-G-G and T-T-G from the A3B SNPs rs2267398-rs2267401-rs2076109 carried a lower risk of HCC than the reference haplotype. These findings suggested that there was no relationship between A3A, A3B and A3H SNPs and CHB progression or HCC development in the Han Chinese population.

 CHB HCC Chinese population SNPs APOBEC3 Introduction

Hepatocellular carcinoma (HCC) is a common form of liver cancer associated with high mortality. It is estimated that ~600,000 new cases are diagnosed annually worldwide; HCC is relatively common in Asia-Pacific countries and sub-Saharan Africa (1). Hepatitis B virus (HBV) infection is believed to be the most common cause of HCC development, with the clinical course of HBV infection often progressing from chronic hepatitis B (CHB) to liver cirrhosis (LC) and then HCC (1). It is estimated that ~2-10% of CHB patients develop LC, some of which subsequently develop HCC; however, some HBV carriers can also spontaneously eliminate the virus (2). HBV infection is common in China due socio-economic factors. As a consequence, the incidence of HCC in China is relatively high, contributing to ~422,100 deaths annually (3).

The apolipoprotein B mRNA-editing catalytic polypeptide-like 3 (APOBEC3, A3) gene cluster is located in chromosome region 22q13.1 to q13.2 (4). This gene cluster encodes seven proteins, including A3A, A3B, A3C, A3DE, A3F, A3G and A3H (5) and is reported to perform important roles in various biological processes, including the innate immune response to viral infections (4,6). Among the seven protein family members, A3A and A3B are able to restrict the infection of a broad range of viruses, including parvovirus, HBV, hepatitis C virus, herpesvirus, human papillomavirus and human immunodeficiency virus 1 (HIV-1) (7–13). A3H is the most polymorphic member of the A3 subfamily, as it has various single nucleotide polymorphism (SNP) combinations that influence protein stability during resistance to HIV-1 infection (14). Besides their role in viral restriction, the dysregulation and hypermutation of A3 genes has recently been linked to carcinogenesis (15). In particular, a 29.5 kb germline deletion of A3A/B was associated with an increased risk of various cancer types, including breast and ovarian cancer. However, the effect has been inconsistent in different populations and for different types of cancer. For example, it has been suggested that the deletion of A3A/B was associated with an increased risk of breast cancer in European women (16), Chinese women (17) and southeast Iranian women (18). However, this association was not observed in Swedish (19) or Moroccan (20) populations, or in the general European population (21). Few studies have investigated the association between A3H polymorphisms and cancer risk. Zhu et al (22) reported that the T allele of the rs139293 A3H SNP was associated with reduced lung cancer risk in a Chinese population; therefore, further studies are required to confirm the associations between A3A, A3B and A3H polymorphisms and HCC risk.

The present study evaluated the associations between the SNPs of A3A, A3B and A3H, and the development of chronic HBV and HBV-related HCC in a Han Chinese population.

 Materials and methods <sec> <title>Study population

Between January 2012 and July 2016, a total of 654 patients from the First Hospital of Jilin University were enrolled in the present study, including 104 patients with CHB, 265 patients with HBV-related LC and 285 patients with HBV-related HCC. The criteria used to diagnose CHB, HBV-related LC and HBV-related HCC have been defined previously (23). Hepatitis A-, C-, D- or E-positive patients and those with HIV were excluded. In addition, patients who had suffered another organ malignancy in the past 5 years, had combined autoimmune diseases, or had other liver diseases, such as intra- and extra-hepatic bile duct stones, alcoholic liver diseases and hemorrhagic liver diseases, were also excluded. General characteristics, including gender, age, smoking history, drinking history, HBV infection history and treatment history, were gathered using a standardized questionnaire. Whole blood (5 ml) was collected from veins of each patient within 48 h of hospital admission and their hepatitis B profile was compiled, including hepatitis B e antigen (HBeAg), hepatitis B e antibody (HBeAb), anti-hepatitis B core antigen (HBc), anti-HBe, hepatitis C, HBV DNA quantification, liver function, renal function, α-fetoprotein, blood lipids, blood glucose, blood routine, coagulation routine and abdominal color Doppler ultrasound (or liver computed tomography or magnetic resonance imaging). Patients were also assessed using the Child-Pugh score (24,25) and those with HCC underwent Barcelona clinic liver cancer staging (26). The present study was approved by the First Hospital Ethical Committee of Jilin University and written informed consent was obtained from all participants.

 SNP selection and genotyping

A3A, A3B and A3H SNPs were selected from the functional regions of the exon, promoter and untranslated regions (UTRs) by GeneView (27) based on Hapmap (https://www.genome.gov/10001688/international-hapmap-project) and the 1,000 Genomes database (http://www.internationalgenome.org/), with a minor allele frequency of >10%. The SNPs rs7286317 and rs7290153 were selected for A3A since they are located in the microRNA-binding site of the 3´UTR. The SNPs rs2267398 and rs2267401, located in the transcription factor-binding site of the promoter region, were selected for A3B due to their potential roles in gene transcription, while the SNP rs2076109 was selected as it is a missense mutation that may regulate gene function by altering the protein structure. The SNPs rs56695217, rs139302, rs139297, rs139316 and rs139292 were selected for A3H because rs56695217 is located in the transcription factor-binding site, and the others are missense mutations. Haplotype analysis was performed using Haploview version 4.2 (http://www.broad.mit.edu/mpg/haploview) with rs2076109 (A3B), rs139297 (A3H), rs139302 (A3H) and rs139316 (A3H) tag-SNPs. The locations of the A3A, A3B and A3H genes and the selected SNPs are shown in Fig. 1.

Genomic DNA was isolated from whole blood using a blood genomic DNA kit (Sigma-Aldrich; Merck KGaA), according to the manufacturer's instructions. SNP genotyping was performed using a MassArray system (Sequenom), according to the manufacturer's protocol. All SNP primers were designed using Assay Designer (http://assay.archerdx.com/, version 3.2; Table I).

 Statistical analysis

All data were analyzed using SPSS version 21.0 (IBM Corp.). Continuous variables are expressed as the mean ± standard deviation or as the median and the interquartile range (25 and 75%). Categorical variables are expressed as a percentage (%). Differences among multiple groups were compared using analysis of variance and the least significant difference multiple comparisons test. Haplotype analysis was performed using Unphased version 3.1.4 (28). The two-sided χ2 test or Fisher's exact test was used to compare allele distributions. Multivariate logistic regression analysis was performed to calculate odds ratios and 95% confidence intervals after adjusting the factors of smoking, drinking and gender differences. P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>General characteristics of the study population

The main general and clinical characteristics of the study population are summarized in Table II. No statistical differences were observed between the sex, age, or the percentage of smokers and alcohol consumers in the CHB and LC patient groups (P<0.05). In comparison, the median age and percentages of smokers and alcohol consumers were significantly higher for HCC patients than for CHB patients (P=0.006, 0.013 and 0.008, respectively); however, no significant difference was observed in their sex distributions. Furthermore, no significant differences were observed in the sex, age and percentage of alcohol consumers between the LC and HCC patients (P<0.05), but the percentage of smokers differed significantly (P<0.001).

No significant differences were observed between the HBeAg positive rate or alkaline phosphatase (ALP) level of the CHB and LC patients. However, the serum HBV-DNA positive rate, HBV load, and alanine transaminase (ALT), aspartate transaminase (AST) and glutamyl transpeptidase (GGT) levels of the CHB patients were significantly higher compared with those of the LC patients (P<0.05), suggesting that hepatocellular damage was more severe in CHB patients. Furthermore, the prealbumin, albumin and cholinesterase levels, and the platelet count were all significantly higher in CHB patients compared with LC patients (P<0.05), while the total bilirubin level was significantly lower in CHB patients compared with LC patients (P<0.05). The HBeAg positive rate, HBV load, ALT level, prealbumin level and total bilirubin level did not differ significantly between LC and HCC patients (P<0.05). Additionally, the levels of AST, ALP, GGT, albumin and cholinesterase, and the platelet count were all significantly lower in LC patients compared with HCC patients (P<0.05), suggesting that the LC patients had a lower level of hepatocellular damage than the HCC patients.

 Associations between genotype and allele frequency in A3A, A3B and A3H SNPs

The genotype and allele frequency of the A3A polymorphisms in CHB patients and healthy individuals are displayed in Table III. No significant associations were detected between the genotype and allele frequency of the two A3A SNPs (rs7286317 and rs7290153) and chronic hepatitis B progression or HCC occurrence (P<0.05). Furthermore, as shown in Tables IV and V, no significant associations were observed between the three A3B SNPs (rs2267398, rs2267401 and rs2076109) or the five A3H SNPs (rs56695217, rs139302, rs139297, rs139316 and rs139292) and chronic hepatitis B progression or HCC occurrence (P<0.05).

 Haplotype analysis of A3A, A3B and A3H

Haplotype analysis was also performed on the two A3A SNPs, three A3B SNPs and five A3H SNPs using Unphased version 3.1.4. No haplotypes were found for the two A3A SNPs or five A3H SNPs (data not shown). The distribution of the A3B haplotype rs2267398-rs2267401-rs2076109 was significantly different between the LC and HCC groups (Table VI). The C-G-G haplotype was used as a reference, with the results showing that the mutant C-T-A, C-T-G, T-G-G and T-T-G haplotypes of rs2267398-rs2267401-rs2076109 were associated with a lower risk of HCC compared with the reference haplotype (Table VII).

 Discussion

It is estimated that ~55% of HCC cases are associated with CHB (29,30). Members of the A3 protein family have been reported to edit the HBV genome and reduce HBV replication in vivo and in vitro (31,32). However, the effects of the SNPs of A3 genes have not yet been evaluated in a Chinese population. To the best of the authors' knowledge, the present study is the first to investigate the association between A3A, A3B and A3H SNPs and the development of CHB and HBV-related HCC in a Chinese population. There were two major findings of the present study: i) The rs7286317 and rs7290153 SNPs of A3A, and the rs56695217, rs139292, rs139297, rs139302 and rs139316 SNPs of A3H, had no relationship with CHB progression or HCC development; and ii) the rs2267398, rs2267401 and rs2076109 SNPs of A3B may not affect the likelihood of CHB progression or HCC development. However, the C-T-A, C-T-G, T-G-G and T-T-G haplotypes of rs2267398-rs2267401-rs2076109 were associated with a lower risk of HCC development than the reference haplotype C-G-G.

APOBEC cytosine deaminases are known to confer innate immunity against retroviruses by generating lethal hypermutations in viral genomes (33). Köck and Blum (31) assessed the ability of A3G, A3C and A3H to edit HBV genomes, finding that each gene could edit HBV DNA and that each protein was likely to contribute (to varying degrees) to genome modification in human liver cells. Previously, it was demonstrated that the A3G rs8177832 SNP was associated with a decreased risk of CHB infection and HCC, while the rs2011861 SNP was associated with an increased risk of HCC (23). Furthermore, it has been shown that A3A is an efficient HBV DNA editor, while A3A and A3B serve crucial roles in inducing the degradation of HBV covalently closed circular DNA (34). Therefore, it was speculated that these three genes may be associated with disease progression following HBV infection.

The present study analyzed the association between A3A, A3B and A3H SNPs and the progression of HBV infection. A total of 654 patients were included in the study, consisting of 104 patients with CHB, 265 patients with HBV-related LC and 285 patients with HBV-related HCC. However, the results demonstrated that the SNPs of these three genes were not associated with disease progression following HBV infection. Haplotype analysis suggested that the C-T-A, C-T-G, T-G-G and T-T-G haplotypes of rs2267398-rs2267401-rs2076109 were associated with a lower risk of HCC compared with the reference haplotype C-G-G. It was hypothesized that this may be due to the linkage between different functional genes. Previous studies have shown that APOBEC-specific mutations are common in tumor genomes (35,36) and that the expression level of APOBEC mRNA is positively correlated with the APOBEC-specific mutation rate (37). In vitro, A3B has been shown to promote the proliferation of the hepatoma cell line HepG2 by upregulating the expression of heat shock protein 1 (38). Therefore, A3B may be the predominant APOBEC-specific mutation-inducing gene in the development of primary liver cancer. Notably, clinical data have demonstrated that the deletion of ~29.5 kb between A3A exon 5 and A3B exon 8 causes the loss of the entire A3B coding region and increases the risk of HCC (39,40). Furthermore, genome sequencing has revealed that A3B deletion can increase the APOBEC-specific mutation rate in the tumor genome (38). Consequently, it has been hypothesized that A3B gene deletion may cause the expression of A3AΔA3B (A3A after A3B deletion) to be more stable and efficient (41,42) and that A3AΔA3B may be the predominant mutagenic factor. Therefore, haplotype changes may affect HCC occurrence by altering the gene expression and editing the functions of A3A and A3B. However, the exact mechanisms by which this occurs requires further investigation.

The present study had a number of limitations. First, healthy controls were not enrolled in this study to evaluate the effect of the A3A, A3B and A3H SNPs on susceptibility to HBV infection. Second, some disease factors were not considered in the present study, such as the age at which HBV infection occurred, which is closely associated with the outcome of HBV infection (43). However, exact HBV infection age data are not available from most places in China due to socioeconomic factors. According to previous studies, ~90% of infants infected perinatally become chronic carriers, unless vaccinated at birth. The risk of CHB decreases to 30% in children infected between ages 1 and 4 years, and to <5% in persons infected as adults (44–46). Therefore, most patients with CHB infection are likely to have been infected in infancy. Since it was not possible to acquire the exact infection age, the present study assumed the age of patients as the length of infection. Therefore, age-matched patients with CHB, HBV-related LC and HBV-related HCC were recruited. Third, the associations were analyzed solely by statistical analysis and were not validated experimentally. Therefore, further studies using larger sample sizes from different populations alongside experimental validation should be conducted to verify the results of the present study.

In conclusion, the present study demonstrated that there was no association between the rs7286317 and rs7290153 SNPs of A3A, the rs2267398, rs2267401 and rs2076109 SNPs of A3B, and the rs56695217, rs139292, rs139297, rs139302 and rs139316 SNPs of A3H and CHB progression or HCC development. However, the C-T-A, C-T-G, T-G-G and T-T-G haplotypes of rs2267398-rs2267401-rs2076109 were associated with a lower risk of HCC than the reference haplotype C-G-G.

 Acknowledgements

Not applicable.

 Funding

The present study was supported by The Youth Development Science Foundation of the First Hospital of Jilin University (grant no. JDYY82017023).

 Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

 Authors' contributions

XH, JN and PG conceived and designed the study. XH, HX and XW acquired the data. HX and JN analyzed and interpreted the data. JW performed the statistical analysis. XH drafted the manuscript. JN and PG revised the manuscript for important intellectual content. All authors given final approval of the version to be published.

 Ethics approval and consent to participate

The present study was approved by the First Hospital Ethical Committee of Jilin University. Written informed consent was obtained from all participants.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 Abbreviations APOBEC3

apolipoprotein B mRNA-editing catalytic polypeptide-like 3

 SNPs

single nucleotide polymorphisms

 HBV

hepatitis B virus

 HCC

hepatocellular carcinoma

 CHB

chronic hepatitis B

 LC

liver cirrhosis

 HIV-1

human immunodeficiency virus 1

 HBeAg

hepatitis B e antigen

 HBeAb

hepatitis B e antibody

 UTRs

untranslated regions

 OR

odds ratio

 CI

confidence intervals

 References SawaiHNishidaNKhorSSHondaMSugiyamaMBabaNYamadaKSawadaNTsuganeSKoikeKGenome-wide association study identified new susceptible genetic variants in HLA class I region for hepatitis B virus-related hepatocellular carcinomaSci Rep87958201810.1038/s41598-018-26217-7297849505962604 ChuCMNatural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinomaJ Gastroenterol Hepatol15(Suppl)E25E30200010.1046/j.1440-1746.2000.02097.x10921378 ChenWZhengRBaadePDZhangSZengHBrayFJemalAYuXQHeJCancer statistics in China, 2015CA cancer J Clin66115132201610.3322/caac.2133826808342 HendersonSFentonTAPOBEC3 genes: Retroviral restriction factors to cancer driversTrends Mol Med21274284201510.1016/j.molmed.2015.02.00725820175 TengBBurantCFDavidsonNOMolecular cloning of an apolipoprotein B messenger RNA editing proteinScience26018161819199310.1126/science.85115918511591 SwantonCMcGranahanNStarrettGJHarrisRSAPOBEC enzymes: Mutagenic fuel for cancer evolution and heterogeneityCancer Discov5704712201510.1158/2159-8290.CD-15-0344260918284497973 DoehleBPSchaferACullenBRHuman APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 VifVirology339281288200510.1016/j.virol.2005.06.00515993456 PrasetyoAASariyatunRRevionoSariYHudiyonoHaryatiSAdnanZAHartonoKageyamaSThe APOBEC3B deletion polymorphism is associated with prevalence of hepatitis B virus, hepatitis C virus, Torque Teno virus, and Toxoplasma gondii co-infection among HIV-infected individualsJ Clin Virol706771201510.1016/j.jcv.2015.07.00926305823 BergerGDurandSFargierGNguyenXNCordeilSBouazizSMuriauxDDarlixJLCimarelliAAPOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cellsPLoS Pathog7e1002221201110.1371/journal.ppat.1002221219662673178557 NakayaYStavrouSBlouchKTattersallPRossSRIn vivo examination of mouse APOBEC3- and human APOBEC3A- and APOBEC3G-mediated restriction of parvovirus and herpesvirus infection in mouse modelsJ Virol9080058012201610.1128/JVI.00973-16273568954988146 MinkahNChavezKShahPMaccarthyTChenHLandauNKrugLTHost restriction of murine gammaherpesvirus 68 replication by human APOBEC3 cytidine deaminases but not murine APOBEC3Virology454-455215226201410.1016/j.virol.2014.02.02224725948 HenryMGuetardDSuspeneRRusniokCWain-HobsonSVartanianJPGenetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3GPLoS One4e4277200910.1371/journal.pone.0004277191693512625395 WarrenCJXuTGuoKGriffinLMWestrichJALeeDLambertPFSantiagoMLPyeonDAPOBEC3A functions as a restriction factor of human papillomavirusJ Virol89688702201510.1128/JVI.02383-1425355878 OhAinleMKernsJALiMMMalikHSEmermanMAntiretroelement activity of APOBEC3H was lost twice in recent human evolutionCell Host Microbe4249259200810.1016/j.chom.2008.07.005187790512608726 GansmoLBRomundstadPHveemKVattenLNik-ZainalSLønningPEKnappskogSAPOBEC3A/B deletion polymorphism and cancer riskCarcinogenesis39118124201810.1093/carcin/bgx13129140415 XuanDLiGCaiQDeming-HalversonSShrubsoleMJShuXOKelleyMCZhengWLongJAPOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestryCarcinogenesis3422402243201310.1093/carcin/bgt185237154973786378 LongJDelahantyRJLiGGaoYTLuWCaiQXiangYBLiCJiBTZhengYA common deletion in the APOBEC3 genes and breast cancer riskJ Natl Cancer Inst105573579201310.1093/jnci/djt018234115933627644 RezaeiMHashemiMHashemiSMMashhadiMATaheriMAPOBEC3 deletion is associated with breast cancer risk in a sample of southeast iranian populationInt J Mol Cell Med41031082015262617994499572 GohlerSDa Silva FilhoMIJohanssonREnquist-OlssonKHenrikssonRHemminkiKLennerPFörstiAImpact of functional germline variants and a deletion polymorphism in APOBEC3A and APOBEC3B on breast cancer risk and survival in a Swedish study populationJ Cancer Res Clin Oncol142273276201610.1007/s00432-015-2038-726320772 MaroufCGohlerSFilhoMIHajjiOHemminkiKNadifiSFörstiAAnalysis of functional germline variants in APOBEC3 and driver genes on breast cancer risk in Moroccan study populationBMC Cancer16165201610.1186/s12885-016-2210-8269201434768349 KlonowskaKKluzniakWRusakBJakubowskaARatajskaMKrawczynskaNVasilevskaDCzubakKWojciechowskaMCybulskiCThe 30 kb deletion in the APOBEC3 cluster decreases APOBEC3A and APOBEC3B expression and creates a transcriptionally active hybrid gene but does not associate with breast cancer in the European populationOncotarget87635776374201710.18632/oncotarget.19400291003175652711 ZhuMWangYWangCShenWLiuJGengLChengYDaiJJinGMaHThe eQTL-missense polymorphisms of APOBEC3H are associated with lung cancer risk in a Han Chinese populationSci Rep514969201510.1038/srep14969264599114602211 HeXTXuHQWangXMHeXSNiuJQGaoPJAssociation between polymorphisms of the APOBEC3G gene and chronic hepatitis B viral infection and hepatitis B virus-related hepatocellular carcinomaWorld J Gastroenterol23232241201710.3748/wjg.v23.i2.232281271975236503 PonsFVarelaMLlovetJMStaging systems in hepatocellular carcinomaHPB (Oxford)73541200510.1080/13651820410024058183331592023920 CholongitasEPapatheodoridisGVVangeliMTerreniNPatchDBurroughsAKSystematic review: The model for end-stage liver disease-should it replace Child-Pugh's classification for assessing prognosis in cirrhosis?Aliment Pharmacol Ther2210791089200510.1111/j.1365-2036.2005.02691.x16305721 SelbyLKTayRXWoonWWLowJKBeiWShelatVGPangTCJunnarkarSPValidity of the barcelona clinic liver cancer and hong kong liver cancer staging systems for hepatocellular carcinoma in singaporeJ Hepatobiliary Pancreat Sci24143152201710.1002/jhbp.42328012284 DohiHIshizukaMMinoshimaSShimizuNGeneView: Multi-language human gene mapping library with a graphical user interfaceComput Appl Biosci945946419938402212 DudbridgeFLikelihood-based association analysis for nuclear families and unrelated subjects with missing genotype dataHum Hered668798200810.1159/000119108183820882386559 CougotDNeuveutCBuendiaMAHBV induced carcinogenesisJ Clin Virol34(Suppl 1)S75S78200510.1016/S1386-6532(05)80014-916461228 FornerALlovetJMBruixJHepatocellular carcinomaLancet37912451255201210.1016/S0140-6736(11)61347-022353262 KockJBlumHEHypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3HJ Gen Virol8911841191200810.1099/vir.0.83507-018420796 SuspeneRGuetardDHenryMSommerPWain-HobsonSVartanianJPExtensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivoProc Natl Acad Sci USA10283218326200510.1073/pnas.040822310215919829 ChiuYLGreeneWCThe APOBEC3 cytidine deaminases: An innate defensive network opposing exogenous retroviruses and endogenous retroelementsAnnu Rev Immunol26317353200810.1146/annurev.immunol.26.021607.09035018304004 LuciforaJXiaYReisingerFZhangKStadlerDChengXSprinzlMFKoppensteinerHMakowskaZVolzTSpecific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNAScience34312211228201410.1126/science.1243462245578386309542 RobertsSALawrenceMSKlimczakLJGrimmSAFargoDStojanovPKiezunAKryukovGVCarterSLSaksenaGAn APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancersNat Genet45970976201310.1038/ng.2702238521703789062 AlexandrovLBNik-ZainalSWedgeDCAparicioSABehjatiSBiankinAVBignellGRBolliNBorgABørresen-DaleALSignatures of mutational processes in human cancerNature500415421201310.1038/nature12477239455923776390 BurnsMBTemizNAHarrisRSEvidence for APOBEC3B mutagenesis in multiple human cancersNat Genet45977983201310.1038/ng.2701238521683902892 XuRZhangXZhangWFangYZhengSYuXFAssociation of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B × antigen mutants and hepatocellular carcinomaHepatology4618101820200710.1002/hep.2189317847074 ZhangTCaiJChangJYuDWuCYanTZhaiKBiXZhaoHXuJEvidence of associations of APOBEC3B gene deletion with susceptibility to persistent HBV infection and hepatocellular carcinomaHum Mol Genet2212621269201310.1093/hmg/dds51323213177 HeXLiJWuJZhangMGaoPAssociations between activation-induced cytidine deaminase/apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like cytidine deaminase expression, hepatitis B virus (HBV) replication and HBV-associated liver disease (Review)Mol Med Rep1264056414201510.3892/mmr.2015.4312263987024626158 ChanKRobertsSAKlimczakLJSterlingJFSainiNMalcEPKimJKwiatkowskiDJFargoDCMieczkowskiPAAn APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancersNat Genet4710671072201510.1038/ng.3378262588494594173 CavalVSuspeneRShapiraMVartanianJPWain-HobsonSA prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3′UTR enhances chromosomal DNA damageNat Commun55129201410.1038/ncomms612925298230 GerlichWHMedical virology of hepatitis B: How it began and where we are nowVirol J10239201310.1186/1743-422X-10-239238704153729363 HyamsKCRisks of chronicity following acute hepatitis B virus infection: A reviewClin Infect Dis209921000199510.1093/clinids/20.4.9927795104 McMahonBJAlwardWLHallDBHeywardWLBenderTRFrancisDPMaynardJEAcute hepatitis B virus infection: Relation of age to the clinical expression of disease and subsequent development of the carrier stateJ Infect Dis151599603198510.1093/infdis/151.4.5993973412 OttJJStevensGAGroegerJWiersmaSTGlobal epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicityVaccine3022122219201210.1016/j.vaccine.2011.12.11622273662

Location of the A3A, A3B and A3H gene and single nucleotide polymorphisms. A3, apolipoprotein B mRNA-editing catalytic polypeptide-like 3 gene family.

Primer sequences for SNP genotyping.

Gene SNPs Primer sequence Annealing temperature (°C)
APOBEC3A rs7286317 F: 5′-ACGTTGGATGGTCAGGAGATCGAGACCATC-3′ 45.1
R: 5′-ACGTTGGATGCACGCCTGGCTAATTTTTTG-3′
rs7290153 F: 5′-ACGTTGGATGGGAAGATTCTTAATTTTGTG-3′ 45.5
R: 5′-ACGTTGGATGGATTATGCTCAATATTCTCAG-3′
APOBEC3B Rs2267398 F: 5′-ACGTTGGATGTTCTCCCTTCCTTGGTGTCG-3′ 46.1
R: 5′-ACGTTGGATGATGCGTCCCCTCTTCCAAC-3′
rs2267401 F: 5′-ACGTTGGATGTCTCTCAGCTGGGTCTGGA-3′ 52.4
R: 5′-ACGTTGGATGGGACCCAACGGAATTGCAAA-3′
rs2076109 F: 5′-ACGTTGGATGAGAGGAAGCACATTTCTGCG-3′ 49.6
R: 5′-ACGTTGGATGTGCTCCCCCTCTCAGAGCAT-3′
APOBEC3H Rs56695217 F: 5′-ACGTTGGATGCCTTGTAATTTGCCCACCTC-3′ 47.0
R: 5′-ACGTTGGATGAAGAACAAAGGCCAGATGCG-3′
Rs139292 F: 5′-ACGTTGGATGTCAGCTGGTAACACAAGAGG-3′ 58.2
R: 5′-ACGTTGGATGAGCCGAAACATTCCGCTTAC-3′
Rs139297 F: 5′-ACGTTGGATGTTGCACCAGTGGTAGTACAG-3′ 48.9
R: 5′-ACGTTGGATGGCTGGTTGACTTCATCAAGG-3′
Rs139302 F: 5′-ACGTTGGATGCAGGACAGTGCCTCACCTT-3′ 49.1
R: 5′-ACGTTGGATGCCTTCAACCCCTATAAGATG-3′
Rs139316 F: 5′-ACGTTGGATGCCAGGGAAAGTCATCTTGAG-3′ 46.7
R: 5′-ACGTTGGATGAAGAAGTTTGCAGCTTGGAC-3′

SNP, single nucleotide polymorphism; F, forward; R, reverse; APOBEC3, apolipoprotein B mRNA-editing catalytic polypeptide-like 3.

General and clinical characteristics of study subjects.

Characteristics CHB n=104 P-valuea LC n=265 P-valueb HCC n=287 P-valuec Reference ranges
Sex (M/F) 84/20 0.823 210/55 0.063 246/41 0.286 –
Aged 47 (43,53) 0.368 49 (41.5,56) 0.901 50 (46,56) 0.006 –
Smokinge 0.862 <0.001 0.013 –
  Have ever smoked 37 (35.6) 91 (34.3) 144 (50.2)
  Have never smoked 67 (64.4) 174 (65.7) 143 (49.8)
Alcohol consumptione 0.142 0.123 0.008 –
  Have ever consumed alcohol 28 (26.9) 93 (35.1) 120 (41.8)
  Have never consumed alcohol 76 (73.1) 172 (64.9) 167 (58.2)
Serum HBV-DNAe 0.002 0.004 0.107 –
  Positive 98 (94.2) 211 (79.6) 254 (88.5)
  Negative 6 (5.8) 55 (20.4) 33 (11.5)
HBV load, log10 (IU/ml)d 6.1 (4.2, 7.3) <0.001 4.6 (2.1, 6.3) 0.565 4.6 (3.1, 6.0) <0.001 1.3–8.2
HBeAge 0.814 0.359 0.295 –
  Positive 43 (48.9) 99 (46.7) 100 (42.2)
  Negative 45 (51.1) 113 (53.3) 137 (57.8)
ALT (U/l)d 172 (53, 496.5) <0.001 42 (24, 86) 0.715 43.5 (27.8, 69.3) <0.001 13.0–35.0
AST (U/l)d 99 (39.5, 249.5) <0.001 47 (31, 90) <0.001 62.0 (38.0,110.0) 0.005 7.0–40.0
ALP (U/l)d 87 (67,122.8) 0.724 89(68,125.5) <0.001 129.5 (86.0,190.5) <0.001 50.0–135.0
GGT (U/l)d 93 (38.3, 161.8) <0.001 49.5 (27, 100.8) <0.001 112.5 (51.3, 254.3) 0.018 7.0–45.0
Prealbumin (g/l)d 0.16 (0.13, 0.20) <0.001 0.12 (0.09, 0.16) 0.192 0.13 (0.08, 0.17) <0.001 0.18–0.39
Albumin (g/l)d 37.5 (32.0, 41.2) <0.001 30.5 (25.3, 36.0) <0.001 33.1 (28.3, 37.3) <0.001 40.0–55.0
Total bilirubin (µmol/l)d 19.6 (13.3, 48.0) 0.035 27.6 (16.2, 61.4) 0.314 25.9 (16.5, 44.2) 0.101 0.0–8.6
Cholinesterase (U/l)d 6,019 (4,343, 8,281) <0.001 3,289 (2,356, 4,744) 0.012 3,918.0 (2,488.3, 5,762.0) <0.001 4,300–12,000
Platelet count (×109/l)d 145 (117, 188) <0.001 77 (53, 121) <0.001 118.5 (78.8, 172.0) <0.001 100–300

CHB vs. LC

LC vs. HCC

CHB vs. HCC, calculated by analysis of variance and the least significant difference multiple comparisons test.

Data are expressed as the median (25, 75%).

Data are expressed as N (%). HBV, hepatitis B virus; CHB, chronic hepatitis B; LC, liver cirrhosis; HCC, hepatocellular carcinoma; ALT, alanine transaminase; AST, aspartate transaminase; ALP, alkaline phosphatase; GGT, glutamyl transpeptidase; M, male; F, female; HBeAg, hepatitis B e antigen.

Genotype and allele frequencies of two SNPs of APOBEC3A.

A, Rs7286317 genotype and allele
CHB patients (n=104) LC patients (n=265) HCC patients (n=287)
SNP N (%) OR (95%Cl) P-valuea   N (%) OR (95%Cl) P-valueb N (%) OR (95%Cl) P-valuec
Number detected n=102 n=265 n=285
AA 75 (73.5) 1 197 (74.3) 1 200 (70.2) 1
AG 27 (26.5) 0.95 (0.56,1.60) 0.85 68 (25.7) 1.30 (0.89,191) 0.18 85 (29.8) 1.24 (0.74,2.08) 0.42
A Allele 177 (86.8) 1 462 (87.2) 485 (85.1) 1
G Allele 27 (13.2) 0.96 (0.60,1.56) 0.88 68 (12.8) 0.84 (0.60,1.18) 0.32 85 (14.9) 0.87 (0.55,1.39) 0.56
B, Rs7290153 genotype and allele
CHB patients (n=104) LC patients (n=265) HCC patients (n=287)
SNP N (%) OR (95%Cl) P-valuea N (%) OR (95%Cl) P-valueb N (%) OR (95%Cl) P-valuec
Number detected n=97 n=246 n=267
CC 78 (80.4) 1 198 (80.5) 1 217 (81.3) 1
CT 14 (14.4) 0.88 (0.44,1.75) 0.72 31 (12.6) 0.83 (0.48,1.47) 0.52 30 (11.2) 0.78 (0.39,1.57) 0.48
TT 5 (5.2) 1.30 (0.46,3.70) 0.62 17 (6.9) 1.02 (0.51,2.04) 0.95 20 (7.5) 1.41 (0.51,3.92) 0.51
CT+TT 19 0.99 (0.55,1.80) 0.97 48 0.90 (0.57,1.41) 0.65 50 0.95 (0.52,1.73) 0.86
C Allele 170 (87.6) 1 427 (86.8) 1 464 (86.9) 1
T Allele 24 (12.4) 1.0 (0.65,1.78) 0.77 65 (13.2) 1.01 (0.70,1.45) 0.96 70 (13.1) 0.94 (0.57,1.54) 0.79

The two-sided χ2 test or Fisher's exact test was used in the comparison of allele distributions.

CHB vs. LC

LC vs. HCC

CHB vs. HCC, adjusted for age, gender, smoking and alcohol consumption by logistic regression analysis. APOBEC3, apolipoprotein B mRNA-editing catalytic polypeptide-like 3; SNPs, single nucleotide polymorphisms; CHB, chronic hepatitis B; LC, liver cirrhosis; HCC, hepatocellular carcinoma; OR, odds ratio; CI, confidence intervals.

Genotype and allele frequencies of three SNPs of APOBEC3B.

A, Rs2267398 genotype and allele
CHB patients (n=104) LC patients (n=265) HCC patients (n=287)
SNP N (%) OR (95%Cl) P-valuea N (%) OR (95%Cl) P-valueb N (%) OR (95%Cl) P-valuec
Number detected n=96 n=256 n=272
CC 28 (29.2) 1 90 (35.2) 1 93 (34.2) 1
CT 50 (52.1) 0.75 (0.44,1.29) 0.31 125 (48.8) 1.11 (0.75,1.63) 0.61 135 (49.6) 0.85 (0.50,1.47) 0.57
TT 18 (18.8) 0.71 (0.35,1.44) 0.34 41 (16.0) 1.15 (0.68,1.94) 0.61 44 (16.2) 0.77 (0.38,1.56) 0.47
CT+TT 68 0.74 (0.44,1.24) 0.26 166 1.12 (0.77,1.61) 0.56 179 0.83 (0.50,1.39) 0.49
C Allele 106 (55.2) 1 305 (59.6) 1 321 (59.0) 1
T Allele 86 (44.8) 0.84 (0.60,1.17) 0.30 207 (40.4) 0.98 (0.76,1.25) 0.85 223 (41.0) 1.17 (0.84,1.63) 0.36
B, Rs2267401 genotype and allele
CHB patients (n=104) LC patients (n=265) HCC patients (n=287)
SNP N (%) OR (95%Cl) P-valuea N (%) OR (95%Cl) P-valueb N (%) OR (95%Cl) P-valuec
Number detected n=102 n=265 n=284
GG 25 (24.5) 1 58 (21.9) 63 (22.2)
GT 29 (28.4) 0.93 (0.49,1.77) 0.82 65 (24.5) 0.89 (0.53,1.46) 0.62 61 (21.5) 0.88 (0.47,1.69) 0.69
TT 48 (47.1) 1.25 (0.70,2.22) 0.45 142 (53.6) 1.00 (0.65,1.54) 0.99 160 (56.3) 1.29 (0.72,2.29) 0.39
GT+TT 77 1.13 (0.66,1.93) 0.67 207 0.97 (0.64,1.46) 0.87 221 1.13 (0.66,1.93) 0.65
G Allele 79 (38.7) 1 181 (34.2) 1 187 (32.9) 1
T Allele 125 (61.3) 1.22 (0.87,1.70) 0.25 349 (65.8) 0.95 (0.74,1.22) 0.67 381 (67.1) 1.00 (0.71,1.42) 0.98
C, Rs2076109 genotype and allele
CHB patients (n=104) LC patients (n=265) HCC patients (n=287)
SNP N (%) OR (95%Cl) P-valuea N (%) OR (95%Cl) P-valueb N (%) OR (95%Cl) P-valuec
Number detected n=94 n=234 n=246
AA 24 (25.5) 1 57 (24.4) 1 54 (22.0) 1
AG 20 (21.3) 1.30 (0.65,2.61) 0.46 62 (26.5) 1.12 (0.67,1.89) 0.67 64 (26.0) 1.70 (0.83,3.50) 0.15
GG 50 (53.2) 0.95 (0.53,1.71) 0.87 115 (49.1) 0.13 (0.72,1.79) 0.59 128 (52.0) 1.21 (0.67,2.21) 0.53
AG+GG 70 1.05 (0.61,1.83) 0.86 177 1.13 (0.73,1.74) 0.58 192 1.03 (0.63,1.69) 0.89
A Allele 68 (36.2) 1 176 (37.6) 1 172 (35.0) 1
G Allele 120 (63.8) 0.94 (0.66,1.37) 0.73 292 (62.4) 0.89 (0.69,1.16) 0.39 320 (65.0) 1.35 (0.76,2.39) 0.31

The two-sided χ2 test or Fisher's exact test was used in the comparison of allele distributions.

CHB vs. LC

LC vs. HCC

CHB vs. HCC, adjusted for age, gender, smoking and alcohol consumption by logistic regression analysis. APOBEC3, apolipoprotein B mRNA-editing catalytic polypeptide-like 3; SNPs, single nucleotide polymorphisms; CHB, chronic hepatitis B; LC, liver cirrhosis; HCC, hepatocellular carcinoma; OR, odds ratio; CI, confidence intervals.

Genotype and allele frequencies of five SNPs of APOBEC3H.

A, Rs56695217 genotype and allele
CHB patients (n=104) LC patients (n=265) HCC patients (n=287)
SNP N (%) OR (95%Cl) P-valuea N (%) OR (95%Cl) P-valueb N (%) OR (95%Cl) P-valuec
Number detected n=89 n=235 n=241
CC 11 (12.4) 1 29 (12.3) 26 (10.8)
CG 76 (85.4) 1.03 (0.49,2.17) 0.94 203 (86.4) 1.26 (0.71,2.25) 0.43 214 (88.8) 1.17 (0.54,2.56) 0.69
GG 2 (2.2) 0.60 (0.09,4.13) 0.60 3 (1.3) 0.34 (0.03,3.64) 0.36 1 (0.4) 0.11 (0.01,1.37) 0.08
CG+GG 78 1.02 (0.48,2.15) 0.96 206 1.25 (0.70,2.22) 0.45 215 1.14 (0.53,2.47) 0.74
C Allele 98 (55.1) 1 261 (55.5) 1 266 (55.2) 1
G Allele 80 (44.9) 0.98 (0.69,1.39) 0.91 209 (44.5) 0.99 (0.76,1.27) 0.92 216 (44.8) 1.00 (0.71,1.42) 0.98
B, Rs139292 genotype and allele
CHB patients (n=104) LC patients (n=265) HCC patients (n=287)
SNP N (%) OR (95%Cl) P-valuea N (%) OR (95%Cl) P-valueb N (%) OR (95%Cl) P-valuec
Number detected n=95 n=247 n=250
DEL 42 (44.2) 1 111 (44.9) 1 112 (44.8) 1
CAA.DEL 53 (55.8) 0.97 (0.60,1.57) 0.90 134 (54.3) 1.04 (0.72,1.49) 0.84 137 (54.8) 1.03 (0.91,0.63) 0.91
CAA 0 (0.0) 0.73 (0.66,0.80) 1.00 2 (0.8) 0.50 (0.60,7.09) 0.68 1 (0.4) 0.73 (0.66,0.80) 1.00
DEL+CAA 53 0.99 (0.61,1.60) 0.95 136 1.03 (0.72,1.48) 0.86 138 1.03 (0.63,1.69) 0.89
DEL Allele 137 (72.1) 1 356 (72.1) 1 361 (72.2) 1
CAA Allele   53 (27.9) 0.69 (1.00,1.46) 1.00 138 (27.9) 0.99 (0.75,1.31) 1.00 139 (27.8) 0.99 (0.69,1.45) 1.00
C, Rs139297 genotype and allele
CHB patients (n=104) LC patients (n=265) HCC patients (n=287)
SNP N (%) OR (95%Cl) P-valuea N (%) OR (95%Cl) P-valueb N (%) OR (95%Cl) P-valuec
Number detected n=102 n=263 n=280
CC 41 (40.2) 1 115 (43.7) 1 118 (42.1) 1
CG 16 (15.7) 0.84 (0.42,1.68) 0.63 38 (14.4) 0.95 (056,1.62) 0.85 36 (12.9) 0.85 (0.42,1.72) 0.65
GG 45 (44.1) 0.87 (0.52,1.44) 0.58 110 (41.8) 1.78 (0.81,1.70) 0.39 126 (45.0) 1.07 (0.64,1.79) 0.79
CG+GG 61 0.86 (0.54,1.38) 0.53 143 1.12 (0.79,1.58) 0.53 174 1.01 (0.63,1.63) 0.97
C Allele 98 (49.4) 1 268 (49.8) 272 (77.0) 1
G Allele 106 (50.6) 0.89 (0.64,1.23) 0.48 258 (50.2) 1.15 (0.89,1.48) 0.28 288 (23.0) 0.98 (0.71,1.35) 0.90
D, Rs139302 genotype and allele
CHB patients (n=104) LC patients (n=265) HCC patients (n=287)
SNP N (%) OR (95%Cl) P-valuea N (%) OR (95%Cl) P-valueb N (%) OR (95%Cl) P-valuec
Number detected n=89 n=229 n=255
CC 34 (38.2) 1 86 (37.6) 1 81 (31.8) 1
CG 20 (22.5) 1.1 (0.57,2.11) 0.79 56 (24.5) 1.38 (0.86,2.20) 0.18 74 (29.0) 1.53 (0.80,2.94) 0.20
GG 35 (39.3) 0.98 (0.55,1.72) 0.93 87 (30.8) 1.25 (0.82,1.91) 0.30 100 (39.2) 1.31 (0.73,2.33) 0.37
CG+GG 55 1.02 (0.61,1.70) 0.94 143 1.30 (0.89,1.90) 0.18 174 1.39 (0.83,2.24) 0.21
C Allele 88 (49.4) 1 228 (49.8) 1 236 (46.3) 1
G Allele 90 (50.6) 0.99 (0.70,1.40) 0.94 230 (50.2) 0.87 (0.68,1.12) 0.28 274 (53.7) 0.88 (0.63,1.24) 0.47
E, Rs139316 genotype and allele
CHB patients (n=104) LC patients (n=265) HCC patients (n=287)
SNP N (%) OR (95%Cl) P-valuea N (%) OR (95%Cl) P-valueb N (%) OR (95%Cl) P-valuec
Number detected n=103 n=263 n=281
CC 17 (16.5) 1 43 (16.3) 1 37 (13.2) 1
CT 46 (44.7) 1.02 (0.52,1.97) 0.96 117 (44.5) 0.26 (0.75,2.10) 0.39 133 (47.3) 1.36 (0.69,2.69) 0.38
TT 40 (38.8) 1.01 (0.51,2.00) 0.97 103 (39.2) 1.24 (0.73,2.10) 0.42 111 (39.5) 1.40 (0.69,2.77) 0.37
CT+TT 86 1.01 (0.54,1.89) 0.97 220 1.25 (0.77,2.03) 0.37 244 1.37 (0.72,2.60) 0.34
C Allele 80 (38.3) 1 203 (38.6) 1 207 (36.8) 1
T Allele 126 (61.2) 1.01 (0.73,1.41) 0.95 323 (61.4) 0.93 (0.73,1.86) 0.55 355 (63.2) 1.09 (0.78,1.51) 0.61

The two-sided χ2 test or Fisher's exact test was used in the comparison of allele distributions.

CHB vs. LC

LC vs. HCC

CHB vs. HCC, adjusted for age, gender, smoking and alcohol consumption by logistic regression analysis. APOBEC3, apolipoprotein B mRNA-editing catalytic polypeptide-like 3; SNPs, single nucleotide polymorphisms; CHB, chronic hepatitis B; LC, liver cirrhosis; HCC, hepatocellular carcinoma; OR, odds ratio; CI, confidence intervals.

Distributions of SNPs of apolipoprotein B mRNA-editing catalytic polypeptide-like 3B in the different groups.

Groups SNPs χ2 df P-value
CHB vs. LC rs2267398-rs2267401 3.87 3 0.276
rs2267398-rs2076109 5.25 3 0.153
rs2267401-rs2076109 2.51 3 0.472
rs2267398-rs226740-rs2076109 7.33 6 0.291
CHB vs. HCC rs2267398-rs2267401 1.01 3 0.798
rs2267398-rs2076109 0.149 3 0.985
rs2267401-rs2076109 0.405 3 0.939
rs2267398-rs2267401-rs2076109 1.764 6 0.940
LC vs. HCC rs2267398-rs2267401 8.210 3 0.042
rs2267398-rs2076109 1.368 3 0.713
rs2267401-rs2076109 3.278 3 0.351
rs2267398-rs2267401-rs2076109 14.25 6 0.027

CHB, chronic hepatitis B; LC, liver cirrhosis; HCC, hepatocellular carcinoma; SNP, single nucleotide polymorphism.

Analysis of the rs2267398-rs2267401-rs2076109 haplotypes of apolipoprotein B mRNA-editing catalytic polypeptide-like 3B in patients with LC and HCC.

Haplotype LC (%) HCC (%) OR (95%CI) P-value
C-G-G 8 (1.1) 9 (5.6) 1
C-T-A 254 (33.8) 56 (34.6) 0.19 (0.07, 0.53) <0.001
C-T-G 191 (25.4) 35 (21.6) 0.16 (0.06, 0.45) <0.001
T-G-A 2 (0.3) 0 (0.0) 0.47 (0.28,0.78) 0.474
T-G-G 246 (32.7) 50 (30.9) 0.18 (0.07, 0.49) <0.001
T-T-A 25 (3.3) 10 (6.2) 0.36 (0.11,1.18) 0.087
T-T-G 26 (3.5) 2 (1.2) 0.07 (0.01, 0.38) 0.001

CHB, hepatitis B virus; LC, liver cirrhosis; HCC, hepatocellular carcinoma; OR, odds ratio; CI, confidence intervals.